MIRM press release
RTPR•02/11/2026•08:02 ET
0
Key Highlights
- ➤Brelovitug AZURE-1 achieved Week 24 combined virologic and ALT endpoint in both dose arms
- ➤Brelovitug 48-week data showed deepening viral suppression and increased ALT normalization
- ➤Volixibat VISTAS met its primary endpoint with significant, clinically meaningful pruritus reductions
- ➤Volixibat improved PSC pruritus without worsening inflammatory bowel disease activity
- ➤LIVMARLI EXPAND met its primary and five secondary endpoints in biliary atresia and rare liver diseases
Expert Statements
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals
“The data we're presenting at The Liver Meeting reflect the depth of our commitment to rare liver diseases and our focus on generating evidence that addresses important needs for patients”
Chris Peetz, Chief Executive Officer of Mirum Pharmaceuticals
“From longer-term treatment responses with brelovitug to new insights into managing cholestatic pruritus, these presentations reinforce the progress we're making while highlighting the significant unmet needs that remain.”
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026
- Late-breaking Phase 3 AZURE-1 and longer-term brelovitug efficacy, safety, and deepening treatment response data highlighted across a broad HDV population, including patients with cirrhosis
Get started
Create a free account to read the full story.